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the CC BY-NC-ND license (http://creaAbstract Ewing sarcoma is the second most common primary bone tumor seen in children
and adolescents, typically presenting between 10 and 20 years of age. Extraosseous sarcomas
of the Ewing family in adults are rare. We report a manifestation of this tumor entity in the
periprostatic tissue of a 33-year-old male and discuss our treatment approach. Transrectal bi-
opsy is a feasible and simple diagnostic tool for unclear pelvic masses. Multi-modal therapy and
central registries are needed to gain knowledge of rare pelvic tumors like Ewing sarcoma.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ewing sarcoma is the second most common primary
bone tumor seen in children and adolescents. However,
extraosseous sarcomas of the Ewing family in adults are
very rare. We report a manifestation of this uncommon
tumor entity in the periprostatic tissue of a 33-year-old
male.s.de (D. Barski).
of Second Military Medical
.11.007
sian Journal of Urology. Producti
tivecommons.org/licenses/by-nc-2. Case presentation
A 33-year-old patient who had recently migrated from
Afghanistan presented to the emergency department with
symptoms of pelvic pain and urinary tract infection
(dysuria, urgency, mild pyuria on dipstick) for several days.
Patient’s past medical history was unremarkable and
without any recollection of exposure to toxic substances or
genetic predisposition. Upon suspicion of a pelvic mass on
transrectal ultrasound during initial assessment, magnetic
resonance imaging (MRI) of the pelvis was performed. It
revealed a 6.0 cm  4.5 cm  4.6 cm mostly solid pelvic
mass showing signs of central necrosis located between
bladder and rectum with suspected infiltration of the
prostate and left internal obturator muscle (Fig. 1).on and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
Figure 1 The 6.0 cm  4.5 cm  4.6 cm mostly solid pelvic
mass on T1-weighted, contrast-enhanced (A) as well as T2-
weighted MRI-study (B). It shows signs of central necrosis and
displacement of bladder and rectum with suspected infiltration
of the prostate and left internal obturator muscle; partly
contrast-filled bladder with placed foley catheter.
Figure 3 Contrast enhanced staging CT-scan of the pelvis (A)
and re-staging 2 months after surgery and first cycle of adju-
vant chemotherapy (B): no signs of residual disease or recur-
rence of the Ewing-like tumor. Urine-diversion via cystostomy-
catheter after closure of the bladderneck.
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MRI, chest/abdominal computed tomography (CT), bone-
scan as well as colonoscopy were performed. Besides
unspecific enlargement of a cervical lymph node on the left
hand side, no signs of metastatic disease were detected.
For further histological evaluation of the mass,
ultrasound-guided transrectal biopsies were obtained.
Upon pathological examination the tumor was preliminarily
described as a “small, round and blue-cell-like tumor” of
the periprostatic soft-tissue infiltrating the capsule of the
prostate without further classification (Fig. 2).
Besides the Ewing’s sarcoma family of tumors, the initial
differential diagnoses included desmoplastic round cell
tumor and neuroendocrine carcinoma. Other possible dif-
ferential diagnoses, such as neuroblastoma, rhabdomyo-
sarcoma as well as non-Hodgkin’s lymphoma [1e3], were
excluded by immunohistochemistry. With a symptomatic
aggressive tumor and in order to get the complete histol-
ogy, an initial surgical resection was chosen. Radical tumor
resection with prostatovesiculectomy, extended regional
lymph node dissection as well as resection of the pelvic
floor were performed using an open retropubic approach.
The bladder neck was then closed and a cystostomy-
catheter was inserted for urine-diversion (Fig. 3).
Course of postoperative recovery was unremarkable. The
intraoperative setting suggested at least an R1-situation,
even though surgical margins were later reported as tumor-
free (R0) by pathology. After further molecular profiling by
a reference pathologist (Prof. Leuschner, Kiel, Germany)Figure 2 Upon pathological examination the transrectal bi-
opsy was preliminarily described as a small-blue-round-cell
tumor and later classified as a Ewing-like tumor of the peri-
prostatic tissue. (A) Nerve fibre infiltration of the tumor
(400); (B) Tumor formation with close proximity to the
prostatic tissue (40).the tumor was shown to hold genetic alterations of the
EWSR1-gene consistent with the tumor of the Ewing sar-
coma family, even though cytokeratin positivity as
expressed by this tumor is a rather uncommon histopatho-
logical feature only found in a minority of cases in this en-
tity [4,5]. Due to the aggressive nature of this disease and
given the likely presence of residual disease an intensive
regime of adjuvant chemotherapy was initiated shortly
after surgery. It consisted of six courses of VIDE (vincristine,
ifosfamide, doxorubicin, etoposide) applied 3-weekly. Most
recent restaging 12 months after surgery and after
completion of the VIDE-regime showed no signs of residual
disease or recurrence. Currently further chemotherapy is
being administered with an alternating VAI- (vincristine,
actinomycin, ifosfamide) and VAC-regime (vincristine,
actinomycin, cyclophosphamide). Continuous remission
provided, a second surgery for definitive orthotopic or
cutaneous continent urinary diversion is intended upon
completion of adjuvant therapy.
3. Discussion
Ewing sarcoma is a rare malignant disease in which cancer
cells are found in the bone or in soft tissue. Approximately
25% of patients with Ewing sarcoma have metastatic dis-
ease at the time of diagnosis. Ewing sarcoma occurs most
frequently in teenagers and young adults, with a male/fe-
male ratio of 1.6:1 [6]. In patients aged 10e19 years, the
incidence is between nine and 10 cases per million people,
the incidence for all ages is even more rare with one case
per million people in the United States. The polymorphism
(EGR2-gene on 10q21.3) associated with the increased risk
is found at a much higher frequency in whites than in blacks
or Asians, possibly explaining the epidemiology of the
relative infrequency of Ewing sarcoma in the latter pop-
ulations [7].
For extraosseous primary tumors, the most common
primary sites of disease include the following: trunk (32%),
extremity (26%), head and neck (18%), retroperitoneum
(16%), other sites (9%). The Surveillance, Epidemiology, and
End Results (SEER) database was used to compare patients
younger than 40 years with Ewing sarcoma who presented
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extraosseous Ewing sarcoma were mostly older (mean age
of 20 years), white and presented axial primary sites [8].
Extraosseous Ewing sarcoma in adults represent an
extremely rare tumor entity with no more than a few
hundred reported cases of various forms of presentation in
terms of localization and stages of disease [9e11]. Overall
no definitive causation of this tumor entity has yet been
identified [12].
In the presented case we had a 33-year-old Asian male
patient with no known exogenic noxae and no known
disposition to genetic diseases in the family.
With tumors of the Ewing family general guidelines
include neoadjuvant chemotherapy with vincristine, doxo-
rubicin and cyclophosphamide, alternating with ifosfamide
and etoposide [13]. Furthermore neoadjuvant radiotherapy
for improved surgical resection as well as adjuvant irradi-
ation with positive surgical margins are viable options in
this disease [14]. Definitive radiotherapy is generally
considered in those cases deemed unsuitable for surgery,
even though the assumed superiority of resection for local
control remains a suspect of ongoing studies [15]. In our
case a solely adjuvant course of regime with initial surgical
resection was chosen mostly due to the uncommon
initial histopathological presentation of the tumor and
therefore an overall inconclusive classification upon pre-
operative needle-biopsy. As rapid proliferation and high-
aggressiveness had to be expected prompt surgical extir-
pation was chosen as primary course of care in order to
provide definitive classification and potentially enable
targeted systemic treatment of the tumor depending on its
entity (e.g., monoclonal antibody therapy in non-Hodgkin’s
lymphoma [16]).
Existing data suggests similar outcome of adult extra-
osseous Ewing sarcoma compared to that of bone-confined
disease in terms of response to multi-modality treatment
and the prognostic factors influencing treatment success
[17,18]. As for the field of urology, individual cases of
extraosseous Ewing sarcomas have also been reported in
the urinary bladder, kidneys, adrenal glands and even the
penis [19e22]. To our knowledge only nine other cases of
(peri-)prostatic Ewing sarcoma are known worldwide being
first described in 2003 [23e31]. Outcome in these patients
was overall very poor with reported survival between as
little as 2 [24] up to 12 months [30]. These survival rates are
significantly inferior compared to outcome in the largest
available prospective, randomized collection of patients
studied today on children or adolescents with extraosseous
Ewing sarcomas: 130 of 2792 patients (under 21 years of
age) registered on three Intergroup Rhabdomyosarcoma
Study clinical trials (IRS-I, -II, and -III) from 1972 to 1991
had an extraosseous Ewing sarcoma. Eight-two percent of
the patients achieved a complete response with 10-
year-overall survival being as high as 62%, 61%, and 77% on
IRS-I, IRS-II, or IRS-III multi-modal therapeutic protocols,
respectively. The therapeutical strategy included mixed
groups with adjuvant and neoadjuvant protocols, and no
subgroup analyses are available [18]. With the lack of larger
randomized control trials and the vast majority of studies
focusing on osseous Ewing sarcomas in children, choosing
the right course of treatment was challenging in this
setting. Retrospectively, a neoadjuvant approach wouldhave most likely been the treatment of choice based on
current evidence. Also adjuvant radiotherapy after suspi-
cion of positive surgical margins could have been consid-
ered. With the patient being in full remission 1 year after
diagnosis and a reported average survival of less than 12
months in comparable cases treated with neoadjuvant
chemotherapy, our adjuvant approach might be regarded at
least non-inferior. Further follow-up could give vital addi-
tional information on the optimal treatment sequence in
this rare tumor entity. In general transrectal or perineal
biopsy seems to be a feasible procedure for the initial
diagnosis of unclear pelvic masses. Given the fact that
sarcoma is a very rare entity, central registries of rare
pelvic tumors would be helpful, in order to get an evidence
based, standardized therapy.
4. Conclusion
Sarcomas are a rare but clinically relevant differential
diagnosis in pelvic masses of the young adult. Histological
confirmation and definitive classification is paramount for
optimal treatment, which should include a multimodal
approach in an interdisciplinary team. Initial surgery fol-
lowed by adjuvant chemotherapy might be an alternative
approach to neoadjuvant treatment.
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